Ultragenyx to Present at Upcoming Investor Conferences
September 03 2020 - 8:31AM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
products for serious rare and ultra-rare genetic diseases, today
announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief
Executive Officer and President, will present at the following
upcoming investor conferences:
- Citi’s 15th Annual BioPharma Virtual Conference as part of a
panel discussion on Wednesday, September 9, 2020 at 4:15 PM ET.
- Morgan Stanley Virtual 18th Annual Global Healthcare Conference
on Tuesday, September 15, 2020 at 12:30 PM ET.
- BofA Securities Virtual Global Healthcare Conference on
Wednesday, September 16, 2020 at 11:45 AM ET.
The live and archived webcast of the presentation will be
accessible from the company’s website at
http://ir.ultragenyx.com/events.cfm. The replay of the webcast will
be available for 90 days.
About Ultragenyx Pharmaceutical Inc. Ultragenyx
is a biopharmaceutical company committed to bringing to patients
novel products for the treatment of serious rare and ultra-rare
genetic diseases. The company has built a diverse portfolio of
approved therapies and product candidates aimed at addressing
diseases with high unmet medical need and clear biology for
treatment, for which there are typically no approved therapies
treating the underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at: www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.Investors &
MediaJoshua Higa415-660-0951
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Apr 2023 to Apr 2024